DOI: 10.1055/s-00034925

Hämostaseologie

Issue 04 · Volume 37 · 2017 DOI: 10.1055/s-007-36432

Editorial

237
Lindhoff-Last, Edelgard; Scharf, Rüdiger E.: Update: Direct oral anticoagulants (DOAC) – their use and clinical management remain a challenge
238
Scharf, Rüdiger E.: Non-factor replacement therapies in hemophilia
238
Konstantinides, RStavros v.: The risiks of interrupting anticoagulation

Review

241
Voigtlaender, Minna; Langer, Florian: Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism Behandlung der tumorassoziierten venösen Thromboembolie mit direkten oralen Antikoagulantien
257
Lindhoff-Last, Edelgard: Direct oral anticoagulants (DOAC) – Management of emergency situations Management von Notfallsituationen
267
Koscielny, Jürgen; Rosenthal, Christoph; von Heymann, Christian: Update on Direct Oral AntiCoagulants (DOACs) Update Direkte Orale AntiKoagulanzien (DOAKs)
277
Benetos, Georgios; Bonou, Maria; Toutouzas, Konstantinos; Diamantopoulos, Panagiotis; Viniou, Nora; Barbetseas, John: Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation Fortschritte im antikoagulativen Management von Patienten bei Kardioversion eines nichtvalvulären Vorhofflimmerns
286
Kcükköylü, Seher; Rump, Lars Christian: DOAC use in patients with chronic kidney disease DOAK bei Patienten mit chronischen Nierenerkrankungen
295
Gosselin, Robert C.; Douxfils, Jonathan; Adcock, Dorothy: Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS) Laborbeurteilung von direkten oralen Antikoagulanzien (DOAKs)

Case Report

302
Göndör, Gabor; Stöllberger, Claudia: Pulmonary embolism four days after interruption of therapy with rivaroxaban Pulmonalembolie vier Tage nach Unterbrechung der Therapie mit Rivaroxaban

Reviewed & Commented

307
Tiede, A.: Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia